Differentiation of local tumor recurrence from radiation-induced changes after stereotactic radiosurgery for treatment of brain metastasis: case report and review of the literature

Radiation Oncology

Maximilian I Ruge³  Norbert Galldiks⁶  Martin Kocher¹  Matthias Schmidt⁴  Tobias Blau⁵  Franziska Dorn²  Philipp Kickingereder³ 

[1] Department of Radiation Oncology, University of Cologne, Cologne, Germany;Department of Radiology, University of Cologne, Cologne, Germany;Department for Stereotaxy and Functional Neurosurgery, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany;Department of Nuclear Medicine, University of Cologne, Cologne, Germany;Department of Neuropathology, University of Cologne, Cologne, Germany;Institute of Neuroscience and Medicine, Research Center Jülich, Jülich, Germany

关键词: Advanced MRI techniques;    PET;    Stereotactic-guided biopsy;    Tumor recurrence;    Radiation-induced changes;    Brain metastases;   

Others  :  1154437
DOI  :  10.1186/1748-717X-8-52

 received in 2012-11-05, accepted in 2013-02-23,  发布年份 2013

【 摘 要 】

Background

Structural follow-up magnetic resonance imaging (MRI) after stereotactic radiosurgery (SRS) for brain metastases frequently displays local changes in the area of applied irradiation, which are often difficult to interpret (e.g., local tumor recurrence, radiation-induced changes). The use of stereotactic biopsy for histological assessment of these changes has a high diagnostic accuracy and can be considered as method of choice. In order to solve this relevant clinical problem non-invasively, advanced MRI techniques and amino acid positron-emission-tomography (PET) are increasingly used.

Case presentation

We report the long-term follow-up of a patient who had been treated with linear accelerator based SRS for cerebral metastases of a lung cancer. Fifty-eight months after SRS, the differentiation of local recurrent brain metastasis from radiation-induced changes using structural MRI was difficult. For further differentiation, perfusion-weighted MRI (PWI), proton magnetic resonance spectroscopy (MRS), and ¹¹C-methyl-L-methionine (MET) PET was performed. Due to artifacts and technical limitations, PWI MRI and MRS findings were not conclusive. In contrast, MET PET findings were suggestive for radiation-induced changes. Finally, a stereotactic biopsy for histological assessment of these changes demonstrated clearly a radiation-induced necrosis and the absence of vital tumor.

Conclusion

The use of stereotactic biopsy for histological assessment of indistinguishable lesions on structural MRI after SRS for treatment of brain metastasis represents a highly reliable method to differentiate local tumor recurrence from radiation-induced changes. In this field, results of studies with both advanced MRI techniques and amino acid PET suggest encouraging results. However, artifacts and technical limitations (e.g., lesion size) are still a problem and comparative studies are needed to investigate the relationship, diagnostic performance, and complementary character of advanced MRI techniques and amino acid PET.

【 授权许可】

   
2013 Kickingereder et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Fokas E, Henzel M, Engenhart-Cabillic R: A comparison of radiotherapy with radiotherapy plus surgery for brain metastases from urinary bladder cancer: analysis of 62 patients. Strahlenther Onkol 2010, 186:565-571.
• [2]Suh JH: Stereotactic radiosurgery for the management of brain metastases. N Engl J Med 2010, 362:1119-1127.
• [3]Meisner J, Meyer A, Polivka B, Karstens JH, Bremer M: Outcome of moderately dosed radiosurgery for limited brain metastases. Report of a single-center experience. Strahlenther Onkol 2010, 186:76-81.
• [4]Hoefnagels FW, Lagerwaard FJ, Sanchez E, Haasbeek CJ, Knol DL, Slotman BJ, Vandertop WP: Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence. J Neurol 2009, 256:878-887.
• [5]Plowman PN: Stereotactic radiosurgery. VIII. The classification of postradiation reactions. Br J Neurosurg 1999, 13:256-264.
• [6]Ruge MI, Kickingereder P, Grau S, Hoevels M, Treuer H, Sturm V: Stereotactic biopsy combined with stereotactic (125)iodine brachytherapy for diagnosis and treatment of locally recurrent single brain metastases. J Neurooncol 2011 Oct, 105(1):109-18. Epub 2011 Apr 11
• [7]Peterson AM, Meltzer CC, Evanson EJ, Flickinger JC, Kondziolka D: MR imaging response of brain metastases after gamma knife stereotactic radiosurgery. Radiology 1999, 211:807-814.
• [8]Huber PE, Hawighorst H, Fuss M, van Kaick G, Wannenmacher MF, Debus J: Transient enlargement of contrast uptake on MRI after linear accelerator (linac) stereotactic radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2001, 49:1339-1349.
• [9]Kocher M, Maarouf M, Bendel M, Voges J, Muller RP, Sturm V: Linac radiosurgery versus whole brain radiotherapy for brain metastases. A survival comparison based on the RTOG recursive partitioning analysis. Strahlenther Onkol 2004, 180:263-267.
• [10]Ruge MI, Kocher M, Maarouf M, Hamisch C, Treuer H, Voges J, Sturm V: Comparison of stereotactic brachytherapy (125 iodine seeds) with stereotactic radiosurgery (LINAC) for the treatment of singular cerebral metastases. Strahlenther Onkol 2011, 187:7-14.
• [11]Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
• [12]Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, Otsuka Y, Sakamoto S, Ohata K, Goto T, Hara M: Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 2003, 98:1056-1064.
• [13]Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, Ohata K: Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008, 49:694-699.
• [14]Ruge MI, Suchorska B, Maarouf M, Runge M, Treuer H, Voges J, Sturm V: Stereotactic 125iodine brachytherapy for the treatment of singular brain metastases: closing a gap? Neurosurgery 2011, 68:1209-1218. discussion 1218–1209
• [15]Dooms GC, Hecht S, Brant-Zawadzki M, Berthiaume Y, Norman D, Newton TH: Brain radiation lesions: MR imaging. Radiology 1986, 158:149-155.
• [16]Serizawa T, Saeki N, Higuchi Y, Ono J, Matsuda S, Sato M, Yanagisawa M, Iuchi T, Nagano O, Yamaura A: Diagnostic value of thallium-201 chloride single-photon emission computerized tomography in differentiating tumor recurrence from radiation injury after gamma knife surgery for metastatic brain tumors. J Neurosurg 2005, 102(Suppl):266-271.
• [17]Galldiks N, Stoffels G, Filss CP, Piroth MD, Sabel M, Ruge MI, Herzog H, Shah NJ, Fink GR, Coenen HH, Langen KJ: Role of O-(2-18F-Fluoroethyl)-L-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis. J Nucl Med 2012, 53:1367-1374.
• [18]Horky LL, Hsiao EM, Weiss SE, Drappatz J, Gerbaudo VH: Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neurooncol 2011, 103:137-146.
• [19]Chao ST, Suh JH, Raja S, Lee SY, Barnett G: The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001, 96:191-197.
• [20]Belohlavek O, Simonova G, Kantorova I, Novotny J Jr, Liscak R: Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression? Eur J Nucl Med Mol Imag 2003, 30:96-100.
• [21]Chernov M, Hayashi M, Izawa M, Ochiai T, Usukura M, Abe K, Ono Y, Muragaki Y, Kubo O, Hori T, Takakura K: Differentiation of the radiation-induced necrosis and tumor recurrence after gamma knife radiosurgery for brain metastases: importance of multi-voxel proton MRS. Minim Invasive Neurosurg 2005, 48:228-234.
• [22]Kimura T, Sako K, Tanaka K, Gotoh T, Yoshida H, Aburano T, Tanaka T, Arai H, Nakada T: Evaluation of the response of metastatic brain tumors to stereotactic radiosurgery by proton magnetic resonance spectroscopy, 201TlCl single-photon emission computerized tomography, and gadolinium-enhanced magnetic resonance imaging. J Neurosurg 2004, 100:835-841.
• [23]Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S: Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2009, 30:367-372.
• [24]Mitsuya K, Nakasu Y, Horiguchi S, Harada H, Nishimura T, Bando E, Okawa H, Furukawa Y, Hirai T, Endo M: Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. J Neurooncol 2010, 99:81-88.
• [25]Truong MT, St Clair EG, Donahue BR, Rush SC, Miller DC, Formenti SC, Knopp EA, Han K, Golfinos JG: Results of surgical resection for progression of brain metastases previously treated by gamma knife radiosurgery. Neurosurgery 2006, 59:86-97. discussion 86–97
• [26]Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS: Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomography. Neurology 1982, 32:1323-1329.
• [27]Lee HY, Chung JK, Jeong JM, Lee DS, Kim DG, Jung HW, Lee MC: Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer. Ann Nucl Med 2008, 22:281-286.
• [28]Thompson TP, Lunsford LD, Kondziolka D: Distinguishing recurrent tumor and radiation necrosis with positron emission tomography versus stereotactic biopsy. Stereotact Funct Neurosurg 1999, 73:9-14.
• [29]Chen W: Clinical applications of PET in brain tumors. J Nucl Med 2007, 48:1468-1481.
• [30]Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, Schwaiger M, Molls M, Wester HJ, Weber WA: An interindividual comparison of O-(2- [(18)F]Fluoroethyl)-L-Tyrosine (FET)- and L-[Methyl-(11)C]Methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys 2011, 81:1049-1058.
• [31]Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ: Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010, 9:906-920.
• [32]Kimura T, Sako K, Tohyama Y, Aizawa S, Yoshida H, Aburano T, Tanaka K, Tanaka T: Diagnosis and treatment of progressive space-occupying radiation necrosis following stereotactic radiosurgery for brain metastasis: value of proton magnetic resonance spectroscopy. Acta Neurochir (Wien) 2003, 145:557-564. discussion 564
• [33]Haroon HA, Patankar TF, Zhu XP, Li KL, Thacker NA, Scott MJ, Jackson A: Comparison of cerebral blood volume maps generated from T2* and T1 weighted MRI data in intra-axial cerebral tumours. Br J Radiol 2007, 80:161-168.
• [34]Lanfermann H, Herminghaus S, Pilatus U, Hattingen E, Zanella F: Value of 1H-MR-spectroscopy in differential diagnosis and grading of intracranial tumours. Dtsch Arztebl 2004, 101:A649-A655.
• [35]Moller-Hartmann W, Herminghaus S, Krings T, Marquardt G, Lanfermann H, Pilatus U, Zanella FE: Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002, 44:371-381.
• [36]Heper AO, Erden E, Savas A, Ceyhan K, Erden I, Akyar S, Kanpolat Y: An analysis of stereotactic biopsy of brain tumors and nonneoplastic lesions: a prospective clinicopathologic study. Surg Neurol 2005, 64(Suppl 2):S82-S88.
• [37]Kreth FW, Muacevic A, Medele R, Bise K, Meyer T, Reulen HJ: The risk of haemorrhage after image guided stereotactic biopsy of intra-axial brain tumours–a prospective study. Acta Neurochir (Wien) 2001, 143:539-545. discussion 545–536